Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer

Trial Profile

A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 May 2019

At a glance

  • Drugs Carboplatin (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Dec 2019.
    • 31 Aug 2018 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
    • 27 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top